BioSpace News Archive

Biohaven Pharma announced that it is completing enrollment today in the first of its two registrational Phase III clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant.

The purpose of the study is to assess the efficacy and to evaluate the safety of anakinra in patients with newly diagnosed Still’s disease, including SJIA and AOSD.

Oxford Genetics will supply Twist with its SnapFast technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.

Becton, Dickinson and Company issued the following statement regarding today’s announcement by Merit Medical Systems that it has signed a definitive agreement to acquire BD’s soft tissue core needle biopsy product line and C. R. Bard’s Aspira product line of tunneled home drainage catheters and accessories, contingent on the completion of the BD acquisition of Bard.

MDNA55, is the Company’s lead immunotherapeutic agent targeting the interleukin-4 receptor which is known to be over-expressed in brain tumors and the tumor micro-environment but not in healthy brain tissue.

The company is strengthening its team as it transitions to a clinical development stage company.

The awards were made on November 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan.

Dr. David C. Dale, MD will present the first clinical data from an on-going study of X4P-001-RD in patients with WHIM Syndrome.

This now makes Insulia available for people using any brand of basal insulin including Lantus, Levemia, Toujeo, Tresiba and Basaglar.

The new study used CNS Vital Signs test to evaluate the effects of Neumentix supplementation on cognitive performance compared to placebo.